This article has been corrected to note that Illumina's test is the third NGS-based companion diagnostic to be approved by the FDA, not the second as previously reported.

NEW YORK (GenomeWeb) – Illumina has received US Food and Drug Administration approval for a companion diagnostic test, which it has been developing with Amgen, to run on its MiSeqDx system, the company said after the close of the market on Thursday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.